What is the Purpose of this Study?
The purpose of this study is to evaluate the investigational use of a drug called belzutifan (MK-6482) in people with certain types of pheochromocytoma/ paraganglioma (PPGL) and pancreatic neuroendocrine tumors (pNET). The study will examine the safety and effectiveness of belzutifan. Researchers also aim to determine whether participants who receive the drug have an extended lifespan. All participants will receive belzutifan tablets, taken once a day by mouth.
Eligibility
- * Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
- * Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
- * Cohort BI: VHL Disease-associated tumors:
Where can I participate?
- CS Cancer at Beverly Hills : Abrahm Levi
- CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi
- CS Cancer at The Angeles Clinic and Research Institute : Abrahm Levi
More about this Clinical Trial
What is the full name of this clinical trial?
MK-6482-015: A Study of MK-6482 Monotherapy in Advanced Pheochromocytoma/Paraganglioma and Pancreatic Neuroendocrine Tumors *